An article recently published in The Journal of Clinical Investigation by the group of Dr. Maria Caffarel and Miguel Servet shows for the first time that the proinflammatory cytokine Oncostatin M (OSM) favors breast cancer progression and metastasis, acting as a messenger between different populations of the tumor microenvironment.